The present invention provides a solid preparation comprising, based on 100 parts by weight of the solid preparation, a self-emulsifying composition comprising 0.1 to 0.5 parts by weight of dutasteride, 6 to 110 parts by weight of oil and 6 to 110 parts by weight of a surfactant, and 5 to 185 parts by weight of a coating excipient having pores accommodating the self-emulsifying composition formed in a surface thereof, and a method of manufacturing the solid preparation.

The present invention provides a solid preparation comprising, based on 100 parts by weight of the solid preparation, a self-emulsifying composition comprising 0.1 to 0.5 parts by weight of dutasteride, 6 to 110 parts by weight of oil and 6 to 110 parts by weight of a surfactant, and 5 to 185 parts by weight of a coating excipient having pores accommodating the self-emulsifying composition formed in a surface thereof, and a method of manufacturing the solid preparation.

The disclosure provides methods, formulations, and apparatus for making and using cannabinoid formulations.

A biological function regulating agent comprises a fermented collagen peptide, and the fermented collagen peptide has at least one action selected from the group consisting of an epidermal metabolism promoting action, a fat accumulation inhibiting action, a fat decomposition promoting action and an action of regulating the amount of adipocytokine in a biological body.

A biological function regulating agent comprises a fermented collagen peptide, and the fermented collagen peptide has at least one action selected from the group consisting of an epidermal metabolism promoting action, a fat accumulation inhibiting action, a fat decomposition promoting action and an action of regulating the amount of adipocytokine in a biological body.

This invention relates to topical compositions for combating ectoparasites and endoparasites in animals, comprising at least one isoxazoline active agent and a pharmaceutically acceptable carrier, optionally in combination with one or more additional active agents. This invention also provides for an improved methods for eradicating, controlling, and preventing parasite infections and infestations in an animal comprising administering the compositions of the invention to the animal in need thereof.

This invention relates to topical compositions for combating ectoparasites and endoparasites in animals, comprising at least one isoxazoline active agent and a pharmaceutically acceptable carrier, optionally in combination with one or more additional active agents. This invention also provides for an improved methods for eradicating, controlling, and preventing parasite infections and infestations in an animal comprising administering the compositions of the invention to the animal in need thereof.

The present invention relates to topical pharmaceutical emulsion compositions comprising a therapeutically effective amount of 3,5-Dihydroxy-4-isopropyl-trans-stilbene or a pharmaceutically acceptable salt thereof, an oil phase, a water phase, a surfactant, and an antioxidant, and wherein the emulsion composition is homogeneous and/or the active is solubilized in the oil phase. The invention also relates to methods of treating a dermatological condition or disorder in a patient by administering the present compositions to the skin of the patient.

The present invention relates to topical pharmaceutical emulsion compositions comprising a therapeutically effective amount of 3,5-Dihydroxy-4-isopropyl-trans-stilbene or a pharmaceutically acceptable salt thereof, an oil phase, a water phase, a surfactant, and an antioxidant, and wherein the emulsion composition is homogeneous and/or the active is solubilized in the oil phase. The invention also relates to methods of treating a dermatological condition or disorder in a patient by administering the present compositions to the skin of the patient.

A composition is described comprising probiotics (live and viable or inactivated bacterial strains) and hyaluronic acid or a salt thereof and related use in prevention, treatment (therapeutic or cosmetic curative) or attenuation of at least one sign or symptom associated with, or caused by, skin aging. Use of the composition is also described in prevention or treatment (therapeutic or cosmetic curative) or attenuation of at least one sign or symptom associated with or caused by a reduction in the immune defences of the skin or by an inflammation/infection of the skin, such as an inflammation induced or caused by UV rays.